胰高血糖素肽1对糖尿病伴高血压患者血压变异性的影响

【摘要】目的 探讨胰高血糖素肽1（GLP-1）对2型糖尿病伴高血压患者血压变异性（BPV）的影响。方法 选取糖尿病伴高血压患者120例，使用GLP-1对其进行治疗，检测患者使用前及使用6个月后体质指数（BMI）、空腹血糖、糖化血红蛋白、血清肌酐、血脂等，并进行24h动态血压监测，得到短时BPV。比较治疗前后的相关指标。结果 使用GLP-1后6个月，患者空腹血糖（mmol/L :7.12±0.64vs9.19±2.78）、糖化血红蛋白（%:7.00±0.14vs8.28±1.32）、BMI（kg/m2: 19.30±3.24vs24.50±4.53）较治疗前下降（P<0.05），达到控制目标。24h收缩压（mmHg :135.02±16.57vs139.52±15.60）、白昼收缩压（mmHg:132.50±14.60vs136.44±14.24）、24h收缩压变异性（mmHg:12.20±1.44vs12.73±1.66）、白昼收缩压变异性（mmHg:11.11±1.48vs11.74±1.52）、白昼舒张压变异性（mmHg:7.03±1.42vs7.43±1.45）也降低（P<0.05）。结论 GLP-1可降低糖尿病伴高血压患者的BPV。

Effects of Glucagon Peptide-1on Blood Pressure Variability in Diabetic Hypertensive Patients

[Abstract] Objective To investigate the role of glucagon peptide-1(GLP-1) in blood pressure variability (BPV) indiabetic hypertensive patients.Methods A total of120diabetic hypertensive patients were included in this study. GLP-1 was used for the treatment. The values of body mass index (BMI), fasting blood glucose, glycosylated hemoglobin, creatine and24-hour ambulatory blood pressure (BP) monitoring were detected before and after treatment with GLP-1for six months. The clinical indices were compared before and after treatment.Results The values of fasting blood glucose (mmol/L:7.12±0.64vs9.19±2.78), glycosylated hemoglobin (%:7.00±0.14vs8.28±1.32) and BMI (kg/m2:19.30±3.24vs24.5±4.53) were de?creased to the normal level after GLP-1treatment for six months (P<0.05). There were significant decrease in the 24-h sys?tolic BP (mmHg:135.02±16.57vs139.52±15.60), daytime systolic BP (mmHg:132.5±14.6vs136.44±14.24), 24-h systolic BP variability (mmHg:12.20±1.44vs12.73±1.66), daytime systolic BP variability (mmHg:11.11±1.48vs11.74±1.52), and daytime diastolic BP variability (mmHg:7.03±1.42vs7.43±1.45) after GLP-1treatment for six months (P<0.05). Conclu?sion GLP-1can decrease BPV in diabetic hypertensive patients.